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Introduction
The monoclonal anti-CD52 antibody alemtu-
zumab mediates its efficacy by antibody and com-
plement-dependent cytotoxicity and results in 
depletion of CD52-positive cells and an altered dis-
tribution of different peripheral T and B immune 
cell subtypes in multiple sclerosis patients.1,2 In 
post-marketing experience, single cases of severe 
clinical exacerbation with respective development 
of tumefactive lesions after alemtuzumab use were 
reported.3,4 In addition, alemtuzumab has failed in 
several cases of neuromyelitis optica.5 For these 
cases, the authors suggested a B cell-mediated pro-
cess causing the clinical and MRI exacerbation, 
since the clinical exacerbation was paralleled by the 
re-appearance of B cells in the periphery. This is of 
special interest as B cells seem to play a significant 
role in multiple sclerosis pathogenesis. B cell-
depleting therapies have been extensively and suc-
cessfully tested in relapsing, remitting and primary 
progressive multiple sclerosis and have already 
been approved with ocrelizumab.
Case report
We report a patient with histopathologically 
proven antibody/complement mediated pattern 
type II multiple sclerosis, in which alemtuzumab 
has been successfully applied as rescue therapy. 
After multiple sclerosis diagnosis in 2006, a 
34-year-old female started interferon-beta treat-
ment. Because of high disease activity she was 
escalated to natalizumab treatment in 2008. The 
JC virus antibody status was positive in December 
2014, and thus therapy was changed to fingoli-
mod in March 2015 because of the high risk of 
developing progressive multifocal leukencepha-
lopathy. One month later she suffered a severe 
relapse with headache, and an MRI presented a 
novel subset of large ring-enhancing lesions 
among otherwise typical multiple sclerosis lesions 
(Figure 1(a), first row). Additional evaluation of 
cerebrospinal fluid (CSF) was negative for JC 
virus DNA testing. A first brain biopsy was per-
formed to exclude opportunistic infections and 
confirmed multiple sclerosis typical lesions with 
signs of active demyelination, allowing this case 
to be classified as multiple sclerosis pattern II 
(antibody/complement mediated). The patient 
was treated with steroids, and fingolimod was 
continued. After an additional relapse, fingoli-
mod was stopped in September 2015 and the 
patient was treated with steroids again. Due to 
vaccination, alemtuzumab initiation was delayed. 
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Subsequently, in October 2015 she suffered 
another severe relapse with hemiparesis and apha-
sia unresponsive to steroids, and plasmapheresis 
necessitating intensive care with intubation. MRI 
revealed an increasing number of contrast-
enhancing lesions in cerebral and spinal MRI 
Figure 1. (a) MRI data. First row: initial MRI 4 months before alemtuzumab revealed inhomogeneous lesions 
pattern including large ring-enhancing lesions in juxtacortical white matter admixed with smaller lesions 
of infrequent nodular enhancement. Second row: MRI prior to alemtuzumab administration revealed new 
enhancing lesions and now extensive brainstem involvement. Third row: MRI 6 months after alemtuzumab 
treatment revealed reduction in lesion size as well as perifocal edema and gadolinium enhancement 
disappearance. Fourth row: 12 months after alemtuzumab, lesion consolidation was found. Formerly acute 
lesions revealed progressive T1 hypointensity.
(b) Biopsy was taken from the subcortical right middle frontal gyrus before alemtuzumab application (pre). 
Multiple sclerosis lesion with involvement of the humoral immune system (type II pattern): HE staining shows a 
macrophage-rich lesion with perivascular inflammation and a reactive gliosis. The lesion is demyelinated (LFB/
PAS stain with missing blue myelin). Numerous macrophages with myelin degradation products in their cytoplasm 
are present, indicating an active demyelinating lesion (anti-proteolipid protein). Within the lesion, T cells are 
located in the perivascular space and within the parenchyma (anti-CD3). Activated complement components (anti-
C9neo) and immunoglobulins (anti-immunoglobulin G) are present with macrophages, indicating a complement/
immunoglobulin mediated demyelination (pattern II; arrows indicate complement and IgG-laden macrophages). 
Scale bar: 100 µm for HE, LFB/PAS and anti-CD3. 50 µm for anti-PLP, anti-c9neo and anti-IgG.
(c) Analysis of peripheral immune cell subtypes and CSF markers: peripheral blood immune cell subtypes 
including CD19+ B cells and CD3+ T cells were evaluated prior to and after alemtuzumab infusion. One 
month before alemtuzumab administration (–1M) lymphocyte counts were still decreased due to previous but 
interrupted fingolimod treatment and were normalized directly before alemtuzumab initiation (pre). CD19+ B 
cells were markedly decreased after the first alemtuzumab cycle but demonstrated an overshooting repopulation 
before the second alemtuzumab cycle (12M). Arrows indicate first and second alemtuzumab application. CSF was 
investigated directly before (pre) and one month (1M) after alemtuzumab. Intrathecal inflammation and damage 
of the blood–brain barrier were markedly decreased after alemtuzumab. Q, quotient. Reference values: CD19+ 
B cell in peripheral blood 0.175–0.575 GPt/L; CD3+ T cell in peripheral blood 1.5–4.0 GPt/L; CSF cell count <5 
MPt/L; total protein 150–450 m/L; QAlbumin 6.5; intrathecal IgG, IgM or IgA synthesis 0%.
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(Figure 1(a), second row). The MRI at this stage 
revealed numerous new acute inflammatory 
lesions of similar pattern as in the initial relapse. 
At this stage, multifocal lesions in the brainstem 
were detectable in the MRI. Inadequate response 
toward the intensive anti-inflammatory therapy 
led to another brain biopsy to rule out other dif-
ferential pathologies than ongoing acute demyeli-
nation. This second biopsy confirmed the highly 
inflammatory, active demyelinating multiple scle-
rosis lesions with antibody/complement deposits 
(multiple sclerosis pattern II) (Figure 1(b)).
The first course of alemtuzumab was performed 
in the intensive care unit. Therapy was well toler-
ated. The clinical condition stabilized rapidly and 
the patient was extubated a few days after alemtu-
zumab treatment. After the second alemtuzumab 
cycle in October 2016 the patient had recovered, 
with an EDSS score of 3.5. MRI demonstrated 
lesion regression with resolved blood–brain bar-
rier disruption, although peripheral B cells dem-
onstrated an overshooting repopulation (Figure 
1(a) third and fourth rows; Figure 1(c)).
Discussion
Characterizing the histopathology of early multi-
ple sclerosis lesions, type II pattern multiple scle-
rosis has been described, involving antibodies 
and complement in lesion formation.6,7 This pat-
tern is often associated with ring-enhancing MRI 
lesions as described in the published cases.3,4,8 
Disease exacerbations in patients with antibody-
mediated central nervous system demyelination 
such as multiple sclerosis pattern II or neuromy-
elitis optica spectrum disorders are known for 
mainly T cell directed multiple sclerosis thera-
pies such as interferon-beta, natalizumab or fin-
golimod.6,9 The exact pathophysiological 
mechanisms for these observations are not yet 
clear, but might have also played a role in the 
three cases reported by Haghikia and colleagues 
and Barton and colleagues.3,4 Due to its mecha-
nism of action, repopulation of distinct B cell 
subtypes is seen even 6 months after alemtu-
zumab application, whereas T cell subtype 
repopulation is delayed and decreased even after 
12 months. Based on the different distribution of 
B and T cells after alemtuzumab, Barton and 
colleagues and Haghikia and colleagues sup-
posed B cell-mediated severe clinical exacerba-
tion. After initial depletion, they documented 
re-appearance of peripheral B cells and con-
cluded relation to clinical disease activity and 
development of tumefactive lesions in MRI, 
especially in B cell-driven multiple sclerosis sub-
types. Here we present a case with underlying B 
cell-driven multiple sclerosis that impressively 
improves after alemtuzumab, although periph-
eral B cell repopulation took place. Although it 
cannot be excluded that disease exacerbation 
during alemtuzumab therapy may occur in single 
patients with a suggested underlying B cell-
driven autoimmunity, our case proves that alem-
tuzumab may act as an effective rescue treatment 
in highly active antibody/complement-mediated 
multiple sclerosis type II patients.
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